RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Seth Y. Ablordeppey to Rats

This is a "connection" page, showing publications Seth Y. Ablordeppey has written about Rats.
Connection Strength

0.485
  1. Bricker BA, Peprah K, Kang HJ, Ablordeppey SY. Evaluation of SYA16263 as a new potential antipsychotic agent without catalepsy. Pharmacol Biochem Behav. 2019 04; 179:55-62.
    View in: PubMed
    Score: 0.097
  2. Sampson D, Bricker B, Zhu XY, Peprah K, Lamango NS, Setola V, Roth BL, Ablordeppey SY. Further evaluation of the tropane analogs of haloperidol. Bioorg Med Chem Lett. 2014 Sep 01; 24(17):4294-7.
    View in: PubMed
    Score: 0.071
  3. Bricker B, Sampson D, Ablordeppey SY. Evaluation of the potential of antipsychotic agents to induce catalepsy in rats: assessment of a new, commercially available, semi-automated instrument. Pharmacol Biochem Behav. 2014 May; 120:109-16.
    View in: PubMed
    Score: 0.069
  4. Bricker B, Jackson T, Boateng B, Zhu XY, Ablordeppey SY. Evaluation of the behavioral and pharmacokinetic profile of SYA013, a homopiperazine analog of haloperidol in rats. Pharmacol Biochem Behav. 2012 Aug; 102(2):294-301.
    View in: PubMed
    Score: 0.061
  5. Ablordeppey SY, Altundas R, Bricker B, Zhu XY, Kumar EV, Jackson T, Khan A, Roth BL. Identification of a butyrophenone analog as a potential atypical antipsychotic agent: 4-[4-(4-chlorophenyl)-1,4-diazepan-1-yl]-1-(4-fluorophenyl)butan-1-one. Bioorg Med Chem. 2008 Aug 01; 16(15):7291-301.
    View in: PubMed
    Score: 0.047
  6. Ablordeppey SY, Lyles-Eggleston M, Bricker B, Zhang W, Zhu X, Goodman C, Roth BL. Evaluation of the eutomer of 4-{3-(4-chlorophenyl)-3-hydroxypyrrolidin-1-yl}-1-(4-fluorophenyl)butan-1-one, {(+)-SYA 09}, a pyrrolidine analog of haloperidol. Bioorg Med Chem Lett. 2006 Jun 15; 16(12):3219-23.
    View in: PubMed
    Score: 0.040
  7. Lyles-Eggleston M, Altundas R, Xia J, Sikazwe DM, Fan P, Yang Q, Li S, Zhang W, Zhu X, Schmidt AW, Vanase-Frawley M, Shrihkande A, Villalobos A, Borne RF, Ablordeppey SY. Design, synthesis, and evaluation of metabolism-based analogues of haloperidol incapable of forming MPP+-like species. J Med Chem. 2004 Jan 29; 47(3):497-508.
    View in: PubMed
    Score: 0.034
  8. Sikazwe DM, Li S, Lyles-Eggleston M, Ablordeppey SY. The acute EPS of haloperidol may be unrelated to its metabolic transformation to BCPP+. Bioorg Med Chem Lett. 2003 Nov 03; 13(21):3779-82.
    View in: PubMed
    Score: 0.034
  9. Ablordeppey SY, Borne RF. Detection of a neurotoxic quaternary pyridinium metabolite in the liver of haloperidol-treated rats. Pharmacol Biochem Behav. 1993 Nov; 46(3):739-44.
    View in: PubMed
    Score: 0.017
  10. Billups J, Jones C, Jackson TL, Ablordeppey SY, Spencer SD. Simultaneous RP-HPLC-DAD quantification of bromocriptine, haloperidol and its diazepane structural analog in rat plasma with droperidol as internal standard for application to drug-interaction pharmacokinetics. Biomed Chromatogr. 2010 Jul; 24(7):699-705.
    View in: PubMed
    Score: 0.013
  11. Salako Q, Ablordeppey SY, Dwuma-Badu D, Thornback JR. Radioiodination and preliminary in vivo investigation of the alkaloid cryptolepine. Int J Appl Radiat Isot. 1985 Dec; 36(12):1003-4.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support